June 27, 2011 | Filed under: Health,News | Posted by:
The experimental, ultra-long-acting insulin degludec substantially reduces the risk of dangerously low blood sugar in people with diabetes, compared with the most widely prescribed long-acting insulin, Lantus, studies show.
Posted by
on June 27, 2011. Filed under Health, News.
You can follow any responses to this entry through the RSS 2.0.
You can skip to the end and leave a response. Pinging is currently not allowed.
Posted by
on June 27, 2011. Filed under